Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30126849 | 0.91 | EGFR (0.45) | EGFRMKNK2RAF1BRAFRPS6KA5 | |
| SCHEMBL23538011 | 0.84 | EGFR (0.54) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30126123 | 0.84 | EGFR (0.49) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30126401 | 0.84 | EGFR (0.54) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30126870 | 0.82 | EGFR (0.47) | EGFRMKNK2RAF1BRAF | |
| SCHEMBL30127446 | 0.80 | EGFR (0.50) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30127607 | 0.80 | EGFR (0.50) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30127372 | 0.79 | MKNK2 (0.46) | EGFRMKNK2RAF1BRAFERBB2 | |
| SCHEMBL30127533 | 0.78 | EGFR (0.48) | EGFRMKNK2RAF1BRAF | |
| SCHEMBL30127640 | 0.77 | EGFR (0.47) | EGFRMKNK2RAF1BRAFERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |